Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Effective innate immune response in natural HIV-1 controllers. Can mimicking lead to novel preventive and cure strategies against HIV-1?

Effective innate immune response in natural HIV-1 controllers. Can mimicking lead to novel... Purpose of reviewHIV-1 controller individuals represents a model that can be useful for the development of novel vaccines and therapies. Initial studies pointed to the involvement of improved adaptive immunity, however, new emerging evidence suggests the contribution of innate cells to effective antiviral responses in spontaneous controllers. Therefore, understanding the alterations on innate cell subsets might be crucial to develop new effective therapeutic strategies.Recent findingsAmong different innate immune cells, dendritic cell (DC) and natural killer (NK) cell are essential for effective antiviral responses. DC from controllers display improved innate detection of HIV-1 transcripts, higher induction of interferons, higher antigen presenting capacities and increased metabolism and higher capacities to induce polyfunctional CD8+ T-cell responses. Such properties have been mimicked by Toll-like receptor ligands and applied to DC-based immunotherapies in humans and in animal models. NK cells from controllers display higher expression of activating receptors promoting increased antibody-dependent cellular cytotoxicity (ADCC) and natural cytotoxicity activities. Neutralizing antibodies in combination with interleukin-15 superagonist or interferon-α can increase ADCC and cytotoxicity in NK cells from HIV-1 progressors.SummaryMimicking DC and NK cell innate profiles in controllers has become a promising strategy to step forward a novel efficient immunotherapy against the HIV-1 infection. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and AIDS Wolters Kluwer Health

Effective innate immune response in natural HIV-1 controllers. Can mimicking lead to novel preventive and cure strategies against HIV-1?

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/effective-innate-immune-response-in-natural-hiv-1-controllers-can-I42PfVUZjZ

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/coh.0000000000000750
Publisher site
See Article on Publisher Site

Abstract

Purpose of reviewHIV-1 controller individuals represents a model that can be useful for the development of novel vaccines and therapies. Initial studies pointed to the involvement of improved adaptive immunity, however, new emerging evidence suggests the contribution of innate cells to effective antiviral responses in spontaneous controllers. Therefore, understanding the alterations on innate cell subsets might be crucial to develop new effective therapeutic strategies.Recent findingsAmong different innate immune cells, dendritic cell (DC) and natural killer (NK) cell are essential for effective antiviral responses. DC from controllers display improved innate detection of HIV-1 transcripts, higher induction of interferons, higher antigen presenting capacities and increased metabolism and higher capacities to induce polyfunctional CD8+ T-cell responses. Such properties have been mimicked by Toll-like receptor ligands and applied to DC-based immunotherapies in humans and in animal models. NK cells from controllers display higher expression of activating receptors promoting increased antibody-dependent cellular cytotoxicity (ADCC) and natural cytotoxicity activities. Neutralizing antibodies in combination with interleukin-15 superagonist or interferon-α can increase ADCC and cytotoxicity in NK cells from HIV-1 progressors.SummaryMimicking DC and NK cell innate profiles in controllers has become a promising strategy to step forward a novel efficient immunotherapy against the HIV-1 infection.

Journal

Current Opinion in HIV and AIDS – Wolters Kluwer Health

Published: Sep 25, 2022

References

  • HLA-B∗57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice
  • Lessons to be learned from natural control of HIV − future directions, therapeutic, and preventive implications
  • Susceptibility to CD8 T-cell-mediated killing influences the reservoir of latently HIV-1-infected CD4 T cells
  • Distinct antibody profiles in HLA-B∗57+, HLA-B∗57- HIV controllers and chronic progressors
  • Potent cell-intrinsic immune responses in dendritic cells facilitate HIV-1-specific T cell immunity in HIV-1 elite controllers
  • A reproducibility-based computational framework identifies an inducible, enhanced antiviral state in dendritic cells from HIV-1 elite controllers
  • Elite control of HIV is associated with distinct functional and transcriptional signatures in lymphoid tissue CD8+ T cells
  • Trained immunity: reprogramming innate immunity in health and disease
  • Toll-like receptors and the control of immunity
  • Role of dendritic cells in natural immune control of HIV-1 infection
  • The role of innate immunity in natural elite controllers of HIV-1 infection
  • Detection of viral infections by innate immunity
  • Posttreatment and spontaneous HIV control
  • T-cell exhaustion in HIV infection
  • Engaging innate immunity in HIV-1 cure strategies
  • Human dendritic cell subsets and function in health and disease
  • Immunological fingerprints of controllers developing neutralizing HIV-1 antibodies
  • Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection
  • Mass cytometry analysis reveals complex cell-state modifications of blood myeloid cells during HIV infection
  • Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers
  • Learning to be elite: lessons from HIV-1 controllers and animal models on trained innate immunity and virus suppression
  • Lymph node migratory dendritic cells modulate HIV-1 transcription through PD-1 engagement
  • Long noncoding RNA MIR4435-2HG enhances metabolic function of myeloid dendritic cells from HIV-1 elite controllers
  • The Intersection Of Epigenetics And Metabolism In Trained Immunity
  • Constitutive resistance to viral infection in human CD141+ dendritic cells
  • Immune correlates of natural HIV elite control and simultaneous HCV clearance-supercontrollers
  • Plasmacytoid dendritic cells reduce HIV production in elite controllers
  • Relationships between IL-17(+) subsets, Tregs and pDCs that distinguish among SIV infected elite controllers, low, medium and high viral load rhesus macaques
  • Natural killer cells in antiviral immunity
  • Natural killer cell subpopulations and inhibitory receptor dynamics in myelodysplastic syndromes and acute myeloid leukemia
  • Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire
  • Immune dysfunctions of CD56 neg NK cells are associated with HIV-1 disease progression
  • Influence of NKG2C genotypes on HIV susceptibility and viral load set point
  • Adaptive NK cell responses in HIV/SIV infections: a roadmap to cell-based therapeutics?
  • Identification of NK cell subpopulations that differentiate HIV-infected subject cohorts with diverse levels of virus control
  • HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV
  • HIV-gp140-specific antibodies generated from indian long-term non-progressors mediate potent ADCC activity and effectively lyse reactivated HIV reservoir
  • Activating killer immunoglobulin receptors and HLA-C: a successful combination providing HIV-1 control
  • Impaired downregulation of NKG2D ligands by nef proteins from elite controllers sensitizes HIV-1-infected cells to antibody-dependent cellular cytotoxicity
  • Changes in NK cell subsets and receptor expressions in HIV-1 infected chronic patients and HIV controllers
  • Combined effects of HLA-B∗57/5801 elite suppressor CD8+ T cells and NK cells on HIV-1 replication
  • Lymph node CXCR5+ NK cells associate with control of chronic SHIV infection
  • Therapeutic vaccines and immunological intervention in HIV infection: a paradigm change
  • PD-1 blockade and TLR7 activation lack therapeutic benefit in chronic simian immunodeficiency virus-infected Macaques on antiretroviral therapy
  • Immunological effector mechanisms in HIV-1 elite controllers
  • Reactivation kinetics of HIV-1 and susceptibility of reactivated latently infected CD4+ T cells to HIV-1-specific CD8+ T cells
  • Myeloid cell-mediated trained innate immunity in mucosal AIDS vaccine development
  • The evolution of dendritic cell immunotherapy against HIV-1 infection: improvements and outlook
  • The use of toll-like receptor agonists in HIV-1 cure strategies
  • TLR-agonist mediated enhancement of antibody-dependent effector functions as strategy for an HIV-1 cure
  • Toll-like receptor (TLR) signaling enables cyclic GMP-AMP synthase (cGAS) sensing of HIV-1 infection in macrophages
  • Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys
  • Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation
  • 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates
  • Crosstalk between R848 and abortive HIV-1 RNA-induced signaling enhances antiviral immunity
  • Toll-like receptor 7 (TLR-7) and TLR-9 agonists improve hepatitis C virus replication and infectivity inhibition by plasmacytoid dendritic cells
  • TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice
  • TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs
  • Poly I:C and STING agonist-primed DC increase lymphoid tissue polyfunctional HIV-1-specific CD8 + T cells and limit CD4 + T-cell loss in BLT mice
  • TLR3-responsive, XCR1+, CD141(BDCA-3)+/CD8α+-equivalent dendritic cells uncovered in healthy and simian immunodeficiency virus-infected rhesus macaques
  • Antiretroviral therapy duration and immunometabolic state determine efficacy of ex vivo dendritic cell-based treatment restoring functional HIV-specific CD8+ T cells in people living with HIV
  • A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity
  • Targeting NK cells for HIV-1 treatment and reservoir clearance
  • Interleukin-15-stimulated natural killer cells clear HIV-1-infected cells following latency reversal ex vivo
  • In vivo activation of human NK cells by treatment with an interleukin-15 superagonist potently inhibits acute in vivo HIV-1 infection in humanized mice
  • Potent in vivo NK cell-mediated elimination of HIV-1-infected cells mobilized by a gp120-bispecific and hexavalent broadly neutralizing fusion protein
  • IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation
  • Interferon alpha enhances NK cell function and the suppressive capacity of HIV-specific CD8 + T cells
  • Antibody cooperative adsorption onto AuNPs and its exploitation to force natural killer cells to kill HIV-infected T cells
  • CD155 on HIV-infected cells is not modulated by HIV-1 Vpu and Nef but synergizes with NKG2D ligands to trigger NK cell lysis of autologous primary HIV-infected cells
  • TIGIT blockade enhances NK cell activity against autologous HIV-1-infected CD4 + T cells